Current Statistics
1,547,435 Total Jobs 263,493 Jobs Today 17,681 Cities 222,734 Job Seekers 146,855 Resumes |
|
|
|
|
|
|
Scottsdale - HonorHealth Research Institute - Medical Oncologists with interest - Scottsdale Arizona
Company: HonorHealth Location: Scottsdale, Arizona
Posted On: 01/17/2025
HonorHealth Research Institute in Collaboration with HonorHealth Health Care SystemScottsdale, Arizona The Division of Cancer Research is seeking Board Certified Medical Oncologist with clinical research expertise/interest in the following areas: Melanoma and Solid Tumor Cellular Therapy to join a Cutaneous Oncology ProgramPancreatic cancer / GI malignanciesWomen's Cancer Research Program lead for the Drug Development ProgramBMT/Cellular Therapies Program Join the preeminent phase 1 oncology drug development program in the Southwest US HonorHealth Research Institute (HRI)Established in 2005, the HonorHealth Research Institute (HRI) is part of a six-hospital not-for-profit integrated healthcare system in the Scottsdale/Phoenix metro area. The HRI Cancer Research Division is affiliated with HonorHealth Cancer Care which is a multi-disciplinary Cancer Care program and delivers primary cancer care to approximately 1/3 of all newly diagnosed cancer patients in the Phoenix metropolitan area.As a partner with the regions only locally owned, locally managed healthcare system with an expansive cancer care footprint, HRI is dedicated to offering patients thoughtful, compassionate care and access to novel treatments through innovative clinical research. The focus of the Division of Cancer Research is on providing access to new and novel clinical trials for patients with relapsed and refractory cancer within the state of Arizona and across the United States. Our collaborators include global biopharmaceutical, biotechnology, medical device, and clinical research organizations.2023 Highlights: - 306 Active Trials
- 48 New Clinical Trials Opened; 255 clinical trials
- 134 Active Investigators and Physicians
- 12 FDA Approvals
- $8.5 Million in Donations to the HonorHealth Foundation to benefit the Research InstituteThe Division of Cancer Research is presently comprised of 3 core elements including:
1) Comprehensive Pancreatic Cancer Program delivering multi-specialty care from new diagnosis through relapsed and refractory disease 2) Cutaneous Oncology Program delivering comprehensive care to patients with various melanoma and nonmelanoma skin cancers including uveal melanoma and 3) Phase 1 program including approximately 50-60 active Phase 1 trials of new targeted drugs, immunotherapeutic agents, chemotherapeutics, bispecific antibody therapy and radioligand trials.HRI Clinical Research Oncologists benefit from being a part of a community-based research program which has access to additional resources with reduced administrative layers and generous philanthropic support. Faculty have the opportunity to join the University of Arizona College of Medicine-Phoenix as adjunct faculty where they serve as preceptors and lecturers for clinical rotations and pre-clinical courses. Melanoma/Solid Tumor Cell Therapy Research Position HRI is seeking a Board-Certified Oncologist to the join the Melanoma and Solid tumor Cellular Therapy Program which sees patients with all types of advanced cutaneous malignancies for both standard of care and clinical trial treatments in collaboration with the HonorHealth Dermatology Residency Program. The program has a special focus on uveal/ocular melanoma with multiple clinical trials and translational research programs focused on this rare tumor. The Research Oncologist will partner with the Melanoma Medical Oncologist and will independently lead Phase 1 &2 clinical trials. The Clinical Research Oncologist will also have the opportunities to participate in and initiate their own translational research activities through collaborations with the Translational Genomic Research Institute (TGen), the University of Arizona (UArizona), Arizona State University (ASU) as well as other regional and national institutions. The successful candidate will have the opportunity to lead early phase clinical trials and participate in novel cellular therapy and bispecific antibody trials.Pancreatic Cancer Research PositionHRI is seeking a Board-Certified Oncologist to join a robust Pancreatic Cancer Research Program which offers comprehensive options for treatment ranging from individuals with newly diagnosed localized pancreatic cancer to those with advanced refractory disease. The program has a focus on early detection of pancreas cancer supported by being a center for PRECEDE and grants from the NIH for the UO1/PCDC program. Additionally, HRI is a site within the PANCAN precision promise consortium. The NCCN guideline therapies of gemcitabine plus nab-paclitaxel, 5FU plus nano liposomal irinotecan, and gemcitabine plus nab-paclitaxel, plus cisplatin all originated at HRI. The successful candidate will have the opportunity to lead pancreas cancer initiatives and work within a multi-disciplinary team. Women's Cancer Research Position HRI is seeking a Board-Certified Medical Oncologist to lead and expand the drug development program for women's cancers including breast cancer and gynecologic oncology malignancies. The successful candidate will advance the existing Phase 2 & 3 Research Programs led by community based board-certified gynecologic oncologists and grow Phase 1 enterprises for patients with relapsed and refractory disease. Bone Marrow Transplant (BMT)/Cellular Therapies PositionHRI is seeking a Board-Certified Oncologist to partner with the HonorHealth s BMT program to offer cellular therapy. BMT is a 24-bed unit which performs over 100 allogenic transplants a year. This partnership provides the infrastructure to deliver cellular therapy. Initiatives have already started in cutaneous oncology with plans to move into solid and hematologic malignancies. The successful candidate will engage with community hematology/oncology partners in the Phoenix metropolitan area supporting expansion of access to current bispecific antibody options for lymphoma and multiple myeloma with a focus on disease or therapeutic approaches. Responsibilities |
|
|
|
|
|
|